Neurosterix emerges with $63M to follow Karuna, Cerevel

Small Swiss biotech Addex Therapeutics is transferring its neuroscience assets and its allosteric modulator platform to a new biotech that has picked up $63 million in a Series A raise.

The 22-year-old publicly traded Addex will own about 20% of the new company called Neurosterix, CEO Tim Dyer said in…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks